Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Aarti Pharmalabs's Equity-to-Asset or its related term are showing as below:
NSE:AARTIPHARM'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.61 Med: 0.68 Max: 0.91
Current: 0.61
During the past 6 years, the highest Equity to Asset Ratio of Aarti Pharmalabs was 0.91. The lowest was 0.61. And the median was 0.68.
NSE:AARTIPHARM's Equity-to-Asset is ranked better than 50.75% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:AARTIPHARM: 0.61
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aarti Pharmalabs Equity-to-Asset Related Terms
Aarti Pharmalabs Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aarti Pharmalabs's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aarti Pharmalabs's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs (NSE:AARTIPHARM) has a Equity-to-Asset of 0.00 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aarti Pharmalabs and its competitors. Over the past decade, Aarti Pharmalabs' Equity-to-Asset has ranged from 0.61 to 0.91. According to the industry distribution chart, Aarti Pharmalabs ranks #495 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 49.3%.
Is Aarti Pharmalabs' Equity-to-Asset too high?
Aarti Pharmalabs' current Equity-to-Asset is 0.00. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 0.91. Based on the distribution chart, Aarti Pharmalabs ranks #495 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #495 out of 1005 companies for Equity-to-Asset. This puts Aarti Pharmalabs in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Historically, Aarti Pharmalabs' own Equity-to-Asset has ranged from 0.61 to 0.91 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹694.69, compared to a current price of ₹829.25 — trading 19.4% above its estimated fair value. The current Equity-to-Asset is 0.00. Aarti Pharmalabs' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹829.25 is trading 19.4% above its estimated GF Value™ of ₹694.69.
GuruFocus considers Aarti Pharmalabs to be Modestly Overvalued.
Key valuation signals for NSE:AARTIPHARM:
Equity-to-Asset: 0.00
GF Value™: ₹694.69 vs. price of ₹829.25 (19.4% above fair value)
No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
53GF Score
Get the complete analysis for NSE:AARTIPHARM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIPHARM has been successfully added to your 
